- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma. (Pubmed Central) - Jun 4, 2022 Group I received AVCF (doxorubicin, vinorelbine, cyclophosphamide, FUra, FA) or FAC (doxorubicin, cyclophosphamide, FUra, FA) followed by TCbF (paclitaxel carboplatin, FUra, FA)...Group II also received trastuzumab and pertuzumab...Unexpected toxicity did not occur. This pilot study suggests that high-dose vitamin B6 enhances antitumor potency of regimens comprising FUra and FA.
- |||||||||| Tedopi (OSE 2101) / OSE Immunotherapeutics, 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
But TEDOPI/OSE2101 boost FOLFIRI (Twitter) - Jun 4, 2022
- |||||||||| Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Trial primary completion date, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Jun 3, 2022 P2, N=18, Recruiting, This pilot study suggests that high-dose vitamin B6 enhances antitumor potency of regimens comprising FUra and FA. Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2021 --> Aug 2023
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Effects Of Exercise Dose On Chemotherapy Induced Physical Dysfunction In Male Mice () - Jun 2, 2022 - Abstract #ACSM2022ACSM_3114; Two weeks of low-dose treadmill exercise was sufficient to reverse chemotherapy induced fatigue without altering deficits in strength. Future studies should examine if the combined effects of aerobic and resistance exercise can improve strength.Acknowledgements: NCI R21-CA231131
- |||||||||| Enrollment open, Metastases: Redefining FOLFIORINOX in Older Pancreatic Cancer Patients (clinicaltrials.gov) - May 30, 2022
P2, N=37, Recruiting, Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Jan 2023 Not yet recruiting --> Recruiting
|